Lantheus Holdings, Inc. (LNTH)

On our desk, the major focal point shifted entirely following Curium's definitive agreement to acquire Lantheus. With the cash offer implying premiums ranging from 21% to 38% over historical VWAPs, the stock has compressed tightly near the agreed transaction price. While Simply Wall St notes indicate it trades somewhat below calculated fair value, the upside is now heavily capped by deal terms. We are advising clients to monitor shareholder and regulatory approvals closely, keeping in mind that FY 2026 guidance and subsequent earnings calls have been suspended.

From a risk management standpoint, taking a position here requires weighing the certainty of the Curium cash buyout against the speculative nature of the Contingent Value Rights (CVRs) worth up to $12.00 per share. The search data indicates that these milestone payments are far from assured and may never be met. Furthermore, once the merger closes, Lantheus ceases to be publicly traded, eliminating any long-term equity participation in its theranostics and Pylarify expansion.

Looking at the operational and financial metrics reported for Q2, Lantheus posted an adjusted EPS of $1.55 versus the $1.30 consensus, alongside revenues of $388.2 million compared to the $363.23 million expectation. Analysts previously debated the durability of Pylarify growth and PSMA PET pricing pressures eroding margins, but these fundamental debates are now secondary to merger arbitrage mechanics and deal completion milestones.